MX2022002446A - Compuestos de pirrolopirimidina inhibidores de perk. - Google Patents

Compuestos de pirrolopirimidina inhibidores de perk.

Info

Publication number
MX2022002446A
MX2022002446A MX2022002446A MX2022002446A MX2022002446A MX 2022002446 A MX2022002446 A MX 2022002446A MX 2022002446 A MX2022002446 A MX 2022002446A MX 2022002446 A MX2022002446 A MX 2022002446A MX 2022002446 A MX2022002446 A MX 2022002446A
Authority
MX
Mexico
Prior art keywords
pyrrolopyrimidine compounds
perk inhibiting
perk
inhibiting
compounds
Prior art date
Application number
MX2022002446A
Other languages
English (en)
Spanish (es)
Inventor
Mark J Mulvihill
An- Hu LI
Matthew David Surman
Original Assignee
Hibercell Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hibercell Inc filed Critical Hibercell Inc
Publication of MX2022002446A publication Critical patent/MX2022002446A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2022002446A 2019-08-29 2020-08-28 Compuestos de pirrolopirimidina inhibidores de perk. MX2022002446A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962893528P 2019-08-29 2019-08-29
PCT/US2020/048621 WO2021041975A1 (en) 2019-08-29 2020-08-28 Perk inhibiting pyrrolopyrimidine compounds

Publications (1)

Publication Number Publication Date
MX2022002446A true MX2022002446A (es) 2022-06-02

Family

ID=72470610

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002446A MX2022002446A (es) 2019-08-29 2020-08-28 Compuestos de pirrolopirimidina inhibidores de perk.

Country Status (12)

Country Link
US (1) US20220356186A1 (cg-RX-API-DMAC7.html)
EP (1) EP4021908A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022546414A (cg-RX-API-DMAC7.html)
KR (1) KR20220066290A (cg-RX-API-DMAC7.html)
CN (1) CN114710956A (cg-RX-API-DMAC7.html)
AU (1) AU2020336975A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022003584A2 (cg-RX-API-DMAC7.html)
CA (1) CA3152508A1 (cg-RX-API-DMAC7.html)
IL (1) IL290889A (cg-RX-API-DMAC7.html)
MX (1) MX2022002446A (cg-RX-API-DMAC7.html)
PH (1) PH12022550491A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021041975A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021041973A1 (en) 2019-08-29 2021-03-04 Hibercell, Inc. Perk inhibiting compounds
CA3182276A1 (en) 2020-05-08 2021-12-02 Halia Therapeutics, Inc. Inhibitors of nek7 kinase
CN117597346A (zh) * 2021-04-05 2024-02-23 哈利亚治疗公司 Nek7抑制剂
JP2024513227A (ja) * 2021-04-05 2024-03-22 ハリア・セラピューティクス・インコーポレイテッド Nek7阻害剤
US20240287081A1 (en) * 2021-06-09 2024-08-29 Icahn School Of Medicine At Mount Sinai Perfluoroalkane substituted pyrazolo[3,4-d]pyrimidin and pyrrolo[2,3-d]pyrimidin compounds and uses thereof
US20250000859A1 (en) 2021-08-25 2025-01-02 Alesta Therapeutics BV Use of gcn2 inhibitors in treating cancer
GB202407386D0 (en) 2024-05-24 2024-07-10 Apollo Ap45 Ltd 1H-pyrazolo(4,3-D)pyrimidine derivatives

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903297A (en) 1973-11-01 1975-09-02 Upjohn Co Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
BR9808281A (pt) * 1997-03-19 2000-05-16 Basf Ag Compostos, composições farmacêuticas, processo para tratar doenças proliferativas e/ou distúrbios do sistema imune e para preparar um composto, e, uso de um composto
US7863444B2 (en) * 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
US8598156B2 (en) 2010-03-25 2013-12-03 Glaxosmithkline Llc Chemical compounds
EP3067356B1 (en) * 2013-11-08 2018-07-04 ONO Pharmaceutical Co., Ltd. Pyrrolo pyrimidine derivative
WO2016004254A1 (en) 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1
WO2016085160A2 (ko) * 2014-11-28 2016-06-02 (주)네오팜 발모촉진용 또는 탈모방지용 조성물
GB201508747D0 (en) * 2015-05-21 2015-07-01 Univ Edinburgh Compounds
WO2017046739A1 (en) * 2015-09-15 2017-03-23 Glaxosmithkline Intellectual Property (No.2) Limited Imidazolidinone derivatives as inhibitors of perk
TW201722957A (zh) * 2015-09-15 2017-07-01 葛蘭素史克智慧財產(第二)有限公司 化學化合物
EP3481831B1 (en) * 2016-07-07 2023-09-06 Daewoong Pharmaceutical Co., Ltd. 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same
SI3612519T1 (sl) * 2017-04-18 2022-04-29 Eli Lilly And Company Fenil-2-hidroksi-acetilamino-2-metil-fenilne spojine

Also Published As

Publication number Publication date
KR20220066290A (ko) 2022-05-24
IL290889A (en) 2022-04-01
BR112022003584A2 (pt) 2022-05-24
CA3152508A1 (en) 2021-03-04
JP2022546414A (ja) 2022-11-04
WO2021041975A1 (en) 2021-03-04
AU2020336975A1 (en) 2022-03-31
PH12022550491A1 (en) 2023-02-06
CN114710956A (zh) 2022-07-05
US20220356186A1 (en) 2022-11-10
EP4021908A1 (en) 2022-07-06

Similar Documents

Publication Publication Date Title
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
CO2019006622A2 (es) Derivados de pirazol como inhibidores de malt1
CY1121360T1 (el) Αναστολεις dna-pk
MX377141B (es) Composiciones y metodos para modular la expresion de pkk.
EA201691134A1 (ru) Новые ингибиторы глутаминазы
EA201792214A1 (ru) Соединения замещенного хиназолина
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
UY37205A (es) Inhibidores de bromodominios
CO2023010023A2 (es) Inhibidores de cdk2 y métodos de uso de los mismos
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
MX389672B (es) Inhibidores de ssao de aminopirimidina
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
BR112022003584A2 (pt) Compostos de pirrolopirimidina inibidores de perk
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
MX2021003450A (es) Metodos para tratar trastornos mieloproliferativos.
BR112022003768A2 (pt) Compostos inibidores de perk
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
EA201992302A1 (ru) Соединения, используемые в качестве ингибиторов alcat1
MX2021003888A (es) Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares.